Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefuroxime
Drug ID BADD_D00407
Description Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Indications and Usage For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Marketing Status approved
ATC Code J01DC02; S01AA27
DrugBank ID DB01112
KEGG ID D00262
MeSH ID D002444
PubChem ID 41375
TTD Drug ID D0Y2IE
NDC Product Code 0143-9567; 0143-9569; 0143-9976; 0143-9568; 0143-9977; 0143-9979
UNII O1R9FJ93ED
Synonyms Cefuroxime | Cephuroxime | Zinacef | Ketocef
Chemical Information
Molecular Formula C16H16N4O8S
CAS Registry Number 55268-75-2
SMILES CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal impairment20.01.03.010--Not Available
Complex regional pain syndrome17.02.07.010; 12.01.12.0040.000215%Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Cardiovascular insufficiency02.11.01.011; 24.06.03.0050.000143%Not Available
Treatment failure08.06.01.0170.000358%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000286%Not Available
Adverse reaction08.06.01.0180.000143%Not Available
Low birth weight baby18.04.02.0030.000143%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000215%Not Available
Cholestatic liver injury09.01.07.0160.000143%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.000143%Not Available
Kounis syndrome24.04.04.020; 10.01.03.037; 02.02.02.0200.002504%Not Available
Macular fibrosis06.09.03.0140.000286%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.001145%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021; 12.03.01.0640.001145%Not Available
Candida infection11.03.03.021--
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.007--Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000501%
Anal incontinence17.05.01.021; 07.01.06.0290.000215%
Alcohol interaction08.06.03.0030.000358%Not Available
Arthritis reactive10.02.01.070; 06.04.05.031; 11.07.01.013; 20.08.02.014; 15.01.09.0040.000215%Not Available
Normal newborn18.08.06.0010.000558%Not Available
Retinal cyst06.09.03.0220.000143%Not Available
Small for dates baby18.04.02.0020.000143%Not Available
Vitritis06.04.06.0130.000215%Not Available
Retinal infarction06.10.01.012; 24.04.10.0080.002504%Not Available
Retinal neovascularisation24.03.07.015; 14.07.01.006; 06.10.01.013; 05.07.01.0060.000215%Not Available
Bradycardia neonatal18.04.07.004; 02.03.02.0190.000143%Not Available
Palatal oedema07.05.04.0080.000143%Not Available
Retinoschisis06.09.03.0250.000429%Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene